The necessity for new biomarker discovery approaches and the need for predictive biomarkers for mTOR inhibitors and VEGF targeted anti-angiogenic therapeutics to improve clinical outcomes and the cost-effectiveness of these drugs in cancer medicine have led the PREDICT consortium to design renal cancer clinical trial endpoints using these agents in parallel with robust tumor genomics, functional genomics and other molecular analyses to accelerate predictive biomarker discovery. This evidence concerns the gene VEGFA and cancer.